Hysterectomy Versus Uterine Preservation for Pelvic Organ Prolapse Surgery (HUPPS)
Prospective Multi-site Cohort Study Investigating Hysterectomy Versus Uterine Preservation for Pelvic Organ Prolapse Surgery: The HUPPS Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Erin A Brennand, MD
- Phone Number: 403-944-1636
- Email: Erin.brennand@albertahealthservices.ca
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada
- Recruiting
- Pelvic Floor Clinic
-
Contact:
- Natalie Scime, MSc
- Email: natalie.scime@ucalgary.ca
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Have diagnosed POP of stage ≥2 using the globally recognized Pelvic Organ Prolapse-Quantification System (POP-Q)
- Elect surgical management of POP
- Demonstrate presence of apical prolapse on clinical exam deemed to require either a hysterectomy and concomitant vaginal vault suspension or uterine suspension to properly address their POP during surgical correction
- Desire no further pregnancy
- Can communicate in English
- Are ≥18 years in age
Exclusion Criteria:
- Prior hysterectomy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Uterine Preservation
|
Uterine preservation through suspension
|
|
Hysterectomy
|
Uterine removal and sewing the vagina upwards
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anatomic failure to correct apical POP
Time Frame: 1 year
|
Descent of the apex (POP-Q point C) equal to or beyond one half of the total vaginal length
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall failure to correct POP
Time Frame: 1 year
|
POP-Q stage ≥2 in any compartment, or re-treatment of POP with physiotherapy, pessary, or repeat surgery
|
1 year
|
|
Subjective failure to correct POP
Time Frame: 6 weeks; 1 year
|
Patient report of bulge symptoms at 6 weeks or 1 year, using one item on the PFDI-20: "Do you usually have a bulge or something falling out that you can see or feel in the vaginal area?"
|
6 weeks; 1 year
|
|
Length of surgery (minutes)
Time Frame: Peri-operative
|
Peri-operative
|
|
|
Estimated blood loss during surgery >500 mL
Time Frame: Peri-operative
|
Peri-operative
|
|
|
Procedural complications
Time Frame: Peri-operative
|
E.g., peri-operative blood transfusion, visceral injury
|
Peri-operative
|
|
Post-operative infection
Time Frame: Peri-operative
|
E.g., abscess, urinary tract infection
|
Peri-operative
|
|
Opioid use in-hospital
Time Frame: Peri-operative
|
Measured by Morphine milliequivalent (mEq)
|
Peri-operative
|
|
Resumption of spontaneous voiding (days)
Time Frame: Peri-operative
|
Peri-operative
|
|
|
Length of post-operative stay (days)
Time Frame: Peri-operative
|
Peri-operative
|
|
|
PROM: Total Pelvic Floor Impact Questionnaire-7 (PFIQ-7) score
Time Frame: 6 weeks; 1 year
|
Change from baseline
|
6 weeks; 1 year
|
|
PROM: Total POP Incontinence Sexual Questionnaire Revised (PISQ-IR) score
Time Frame: 6 weeks; 1 year
|
Change from baseline
|
6 weeks; 1 year
|
|
PROM: Total Pelvic Floor Distress Inventory-20 (PFDI-20) score
Time Frame: 6 weeks; 1 year
|
Change from baseline
|
6 weeks; 1 year
|
|
Presentation at the emergency department
Time Frame: 30 days (any health complaint); 1 year (pelvic floor-related complaint)
|
30 days (any health complaint); 1 year (pelvic floor-related complaint)
|
|
|
Hospital readmission
Time Frame: 30 days (any health complaint); 1 year (pelvic floor-related complaint)
|
30 days (any health complaint); 1 year (pelvic floor-related complaint)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- REB19-2134
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.